Lipid 88
Version 1.f05622a8 · 2026-09-13
| CAS No. | Not available |
| Chemical Name | Lipid 88 |
| Synonyms | tetrakis(2-((((2-butyloctyl)oxy)carbonyl)oxy)ethyl) 3,3',3'',3'''-(((methylazanediyl)bis(propane-3,1-diyl))bis(azanetriyl))tetrapropionate;Lipid-88， Lipid 88 |
| SMILES | CCCCCCC(CCCC)COC(OCCOC(CCN(CCC(OCCOC(OCC(CCCC)CCCCCC)=O)=O)CCCN(C)CCCN(CCC(OCCOC(OCC(CCCC)CCCCCC)=O)=O)CCC(OCCOC(OCC(CCCC)CCCCCC)=O)=O)=O)=O |
| Formula | C79H147N3O20 |
| M.Wt | 1,459.0 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Ye, Z., Bonam, S.R., McKay, L.G.A., et al. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. Proc. Natl. Acad. Sci. USA 120(52), e2311752120 (2023). |
Lipid88 is a high-performance, novel ionizable lipid component engineered for advanced mRNA-LNP vaccine delivery. LNP88 formulation demonstrates superior biodistribution, achieving >10-fold higher transfection efficiency in spleen and lymph nodes compared to benchmark lipids like ALC-0315 via intramuscular delivery. When encapsulating antigen-encoding mRNA (e.g., optimized mCSA construct), Lipid-88 based LNPs drive robust humoral and cellular immunity, enabling complete protection against challenging SARS-CoV-2 variants (WA1/2020, Omicron BA.1, BQ.1) in preclinical models. Its design prioritizes potent immunogenicity with favorable safety profiles.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →